Cargando…
1146. Cost-effectiveness of the Pentavalent Meningococcal Vaccine (MenABCWY): A steady-state cohort modelling approach
BACKGROUND: Invasive meningococcal disease (IMD) is associated with a high case fatality rate and serious long-term sequelae (LTS). The current US vaccination platform targets serogroups ACWY with a routine recommendation in adolescents (11-12 years, with a booster at 16 years) and serogroup B (16-2...
Autores principales: | Schley, Katharina, Presa, Jessica V, Snow, Vincenza, Cane, Alejandro D, Peyrani, Paula, Farkouh, Ray, Sullivan, Shannon M, Zivaripiran, Hossein, Teloian, Diana, Möller, Jörgen, Caro, J Jaime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676960/ http://dx.doi.org/10.1093/ofid/ofad500.987 |
Ejemplares similares
-
1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine
por: Cai, Bing, et al.
Publicado: (2023) -
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults
por: Sáez-Llorens, Xavier, et al.
Publicado: (2018) -
6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
por: Peterson, James, et al.
Publicado: (2020) -
Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review
por: Marshall, Gary S., et al.
Publicado: (2022) -
1084 Persistence of Meningococcal Antibodies and Response to a Booster Dose after a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
por: Saez-Llorens, Xavier, et al.
Publicado: (2014)